

Electronic Supplementary Information (ESI) for

Oxidative nucleophilic strategy for synthesis of thiocyanates and trifluoromethyl sulfides from thiols


Kazuya Yamaguchi, Konomi Sakagami, Yumi Miyamoto, Xiongjie Jin and
Noritaka Mizuno*

*Department of Applied Chemistry, School of Engineering, The University of Tokyo, 7-3-1
Hongo, Bunkyo-ku, Tokyo 113-8656*

E-mail: tmizuno@mail.ecc.u-tokyo.ac.jp

Preparation of OMS-2

An aqueous solution of KMnO_4 (5.89 g, 100 mL) was added to an aqueous solution (30 mL) containing $\text{MnSO}_4 \cdot \text{H}_2\text{O}$ (8.8 g) and concentrated HNO_3 (3 mL). The resulting mixture was refluxed at 100 °C for 24 h. Then, the dark brown solid formed was filtered off, washed with a large amount of water (ca. 3 L), and dried under air at 120 °C, affording 8.2 g of OMS-2. The content of Mn in OMS-2 was 58.8 wt%. The BET surface area was $94.0 \text{ m}^2 \text{ g}^{-1}$. The structure and XRD pattern of OMS-2 are shown in Figs S4 and S7, respectively.

Table S1 Oxidative homocoupling of cyclohexanethiol (**1a**)^a

Entry	Metal oxide or salt	Solvent	Yield (%) ^b
1	MgO	Acetonitrile	<1
2	Al ₂ O ₃	Acetonitrile	<1
3	SiO ₂	Acetonitrile	<1
4	Sc ₂ O ₃	Acetonitrile	<1
5	TiO ₂	Acetonitrile	<1
6	V ₂ O ₅	Acetonitrile	<1
7	Cr ₂ O ₃	Acetonitrile	<1
8	OMS-2	Acetonitrile	95
9 ^c	OMS-2	Acetonitrile	80
10	OMS-2	THF	91
11	OMS-2	DMF	96
12	OMS-2	DMAc	>99
13	OMS-2	Ethanol	70
14	OMS-2	Dichloromethane	50
15	OMS-2	Chloroform	26
16	OMS-2	<i>n</i> -Hexane	35
17	OMS-2	Toluene	14
18	β-MnO ₂	Acetonitrile	<1
19	Birnessite-type MnO ₂	Acetonitrile	<1
20	Fe ₂ O ₃	Acetonitrile	<1
21	Co ₃ O ₄	Acetonitrile	2
22	NiO	Acetonitrile	5
23	CuO	Acetonitrile	17
24	ZnO	Acetonitrile	<1
25	MoO ₃	Acetonitrile	<1
26	WO ₃	Acetonitrile	<1
27 ^d	KF	Acetonitrile	<1

^a Reaction conditions: Metal oxide (50 mg), **1a** (0.5 mmol), solvent (2 mL), 30 °C, O₂ (1 atm), 5 min.

^b Yields were determined by GC using naphthalene as the internal standard. In all cases, **2a** was selectively produced without formation of any byproducts. ^c OMS-2 (10 mg), 60 °C. ^d KF (0.13 mmol).

Table S2 Metal oxides used in this study

Metal oxide	Literature or company; note
OMS-2	See the Experimental Section (see Refs. 13,14); BET: 94.0 m ² g ⁻¹
Birnessite-type MnO ₂	Prepared according to Ref. 16; BET: 62.2 m ² g ⁻¹
β-MnO ₂	Obtained from Aldrich (No. 529664-5G); BET: 2.6 m ² g ⁻¹
MgO	Obtained from Kanto (No. 25018-33)
Al ₂ O ₃	Obtained from Sumitomo Chemical (No. KHS-24)
SiO ₂	Obtained from Fuji Silysia Chemical (No. CARiACT Q-10)
Sc ₂ O ₃	Obtained from Aldrich (No. 307874-1G)
TiO ₂	Obtained from Ishihara Sangyo Kaisya (No. ST-01)
V ₂ O ₅	Obtained from KANTO (No. 44017-30)
Cr ₂ O ₃	Obtained from nacalai tesque (No. 08909-22)
Fe ₂ O ₃	Obtained from Alfa Aesar (No. 12593)
Co ₃ O ₄	Obtained from Wako (No. 039-08792)
NiO	Obtained from Aldrich (No. 637130-25G)
CuO	Obtained from Wako (No. 036-09461)
ZnO	Obtained from Wako (No. 260-01261)
MoO ₃	Obtained from Wako (No. 138-03352)
WO ₃	Obtained from Aldrich (No. 550086-5G)









Fig. S1 Examples of (a) naturally found bioactive thiocyanates, (b) thiocyanate drugs, and (c) utilization of thiocyanates as synthons.¹




Trifluoromethionine




Toltrazuril




Fipronil



Losartan (derivative)



Cyclapolin 1



Cephalosporin (derivative)

Fig. S2 Examples of trifluoromethyl sulfide-based drugs and drug candidates.^{2,3}




Fig. S3 Synthetic procedures of Togni's (trifluoromethylation)¹¹ and Shen's (trifluoromethylthiolation)^{12a} reagents.




Fig. S4. (A) Structure and (B) SEM image of OMS-2. The octahedra indicate the $\{\text{MnO}_6\}$ units.^{13,14}




Fig. S5 ESR spectrum of the reaction mixture. OMS-2 was added into a quartz cell (4 mm ID). Then, a toluene solution of **1h** and α -phenyl-*tert*-butylnitron (PBN) (ca. 1 mL, 0.25 M) was added, and the spectrum was measured at measured at $-20\text{ }^{\circ}\text{C}$ (frequency: 9.16 GHz). Two sets of signals assignable to the spin adduct between PBN and the thiyl radical species ($A_N = 1.3\text{ mT}$, ◆) and the oxidized PBN ($A_N = 0.85\text{ mT}$, ▲). See: G. R. Buttner, *Free Radical Biol. Med.*, 1987, **3**, 259–303.




Fig. S6. Reaction profile for the cyanation of **1h**. Reaction conditions: OMS-2 (50 mg), **1h** (0.5 mmol), TMSCN (2 mmol), DMF (2 mL), 30 °C, O₂ (1 atm).






Fig. S7 XRD patterns of fresh and used OMS-2.


Spectral data of disulfides, thiocyanates, and trifluoromethyl sulfides




Compound 2a (Table 1, entries 1 and 2): MS (EI): m/z (%): 230 (8) [M^+], 148 (30), 84 (6), 83 (90), 81 (6), 67 (6), 55 (100), 54 (5), 53 (9).




Compound 2b (Table 1, entry 3): MS (EI): m/z (%): 235 (7), 234 (45) [M^+], 152 (8), 151 (7), 150 (80), 118 (6), 117 (64), 115 (6), 87 (11), 86 (7), 85 (100), 83 (13), 82 (6), 81 (9), 79 (11), 73 (7), 69 (9), 67 (6), 61 (9), 60 (8), 59 (9), 57 (74), 56 (12), 55 (76), 53 (8).




Compound 2c (Table 1, entry 4): MS (EI): m/z (%): 290 (18) [M^+], 178 (15), 145 (21), 87 (10), 71 (74), 70 (6), 69 (27), 67 (8), 57 (100), 56 (9), 55 (39).




Compound 2d (Table 1, entry 5): MS (EI): m/z (%): 246 (3) [M^+], 92 (8), 91 (100), 65 (17).




Compound 2e (Table 1, entries 6 and 7): MS (EI): m/z (%): 219 (7), 218 (47) [M^+], 185 (13), 154 (24), 140 (6), 111 (5), 110 (10), 109 (100), 108 (9), 77 (9), 69 (14), 65 (38), 51 (10).




Compound 2f (Table 1, entry 8): MS (EI): m/z (%): 248 (5), 247 (9), 246 (51) [M^+], 125 (5), 124 (18), 123 (100), 122 (27), 121 (26), 97 (6), 91 (26), 89 (12), 79 (26), 78 (19), 77 (60), 69 (10), 65 (16), 63 (13), 53 (6), 51 (15).




Compound 2g (Table 1, entry 9): MS (EI): m/z (%): 248 (6), 247 (10), 246 (59) [M^+], 213 (10), 198 (10), 182 (15), 167 (10), 125 (5), 124 (13), 123 (100), 122 (8), 121 (20), 97 (8), 91 (22), 89 (8), 79 (35), 78 (15), 77 (43), 69 (9), 65 (15), 63 (10), 53 (6), 51 (10).




Compound 2h (Table 1, entry 10): MS (EI): m/z (%): 246 (22) [M^+], 125 (5), 124 (13), 123 (100), 122 (8), 121 (11), 108 (7), 97 (5), 91 (15), 89 (5), 79 (42), 78 (12), 77 (40), 69 (9), 65 (15), 63 (7), 51 (7).




Compound 2i (Table 1, entry 11): MS (EI): m/z (%): 278 (20) [M^+], 141 (5), 140 (10), 139 (100), 124 (11), 96 (21), 95 (20), 77 (5), 70 (8), 69 (6).




Compound 2j (Table 1, entry 12): MS (EI): m/z (%): 288 (12), 287 (2) [M^+], 286 (15), 145 (26), 144 (7), 143 (72), 110 (5), 109 (10), 108 (100), 107 (7), 101 (7), 99 (24), 82 (12), 75 (12), 73 (10), 69 (13), 63 (14).




Compound 2k (Table 1, entry 13): MS (EI): m/z (%): 320 (6), 319 (12), 318 (49) [M^+], 285 (6), 255 (8), 254 (36), 253 (7), 160 (18), 159 (55), 128 (6), 116 (12), 115 (100), 114 (6), 89 (6).




Compound 2l (Table 1, entry 14): MS (EI): m/z (%): 222 (5), 221 (7), 220 (52) [M^+], 187 (14), 156 (46), 155 (22), 142 (7), 130 (7), 129 (11), 110 (13), 84 (8), 83 (25), 82 (11), 79 (10), 78 (100), 69 (7), 67 (7), 58 (5), 57 (20), 52 (29), 51 (94), 50 (21).




Compound 3b (Table 3, entry 1): MS (EI): m/z (%): 143 (0.14) [M^+], 142 (1.3), 128 (9), 117 (6), 116 (78), 115 (6), 114 (13), 110 (17), 101 (35), 100 (18), 96 (5), 88 (8), 87 (61), 86 (6), 85 (9), 84 (11), 83 (9), 82 (12), 72 (12), 69 (35), 68 (5), 67 (8), 60 (16), 59 (13), 58 (7), 57 (42), 56 (100), 55 (82), 54 (12), 53 (9).




Compound 3c (Table 3, entry 2): MS (EI): m/z (%): 144 (34), 143 (7), 138 (5), 129 (7), 128 (6), 124 (11), 115 (21), 114 (9), 112 (6), 110 (16), 102 (7), 101 (61), 100 (8), 97 (5), 96 (10), 88 (6), 87 (33), 84 (15), 83 (40), 82 (12), 72 (9), 71 (27), 70 (42), 69 (59), 68 (20), 67 (12), 60 (12), 59 (7), 57 (53), 56 (64), 55 (100), 54 (12), 53 (8). ^1H NMR (500.16 MHz, CDCl_3): δ 2.95 (t, $J = 7.0$ Hz, 2H), 1.82 (quin, $J = 7.0$ Hz, 2H), 1.41–1.47 (m, 2H), 1.24–1.36 (m, 8H), 0.89 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (125.77 MHz, CDCl_3): δ 112.43 (SCN), 34.14, 31.75, 29.95, 29.08, 28.90, 28.01, 22.65, 14, 10.




Compound 3d (Table 3, entry 3): MS (EI): m/z (%): 149 (6) [M^+], 92 (9), 91 (100) [$(M - \text{SCN})^+$], 65 (16), 63 (5). ^1H NMR (500.16 MHz, CDCl_3): δ 7.33–7.39 (m, 5H), 4.13 (s, 2H). ^{13}C NMR (125.77 MHz, CDCl_3): δ 134.44, 129.18, 129.03, 128.94, 112.04 (SCN), 38.38.




Compound 3e (Table 3, entries 4 and 5): MS (EI): m/z (%): 137 (5), 136 (9), 135 (100) [M^+], 108 (33), 91 (24), 84 (6), 77 (44), 74 (5), 69 (7), 65 (8), 51 (23), 50 (11). ^1H NMR (500.16 MHz, CDCl_3): δ 7.51–7.53 (m, 2H), 7.39–7.45 (m, 3H). ^{13}C NMR (125.77 MHz, CDCl_3): δ 130.32, 130.15, 129.62, 124.52, 110.60 (SCN).




Compound 3h (Table 3, entries 6–9): MS (EI): m/z (%): 151 (5), 150 (11), 149 (100) [M^+], 148 (15), 123 (6), 122 (6), 121 (12), 117 (7), 116 (63), 92 (6), 91 (74), 90 (5), 89 (13), 78 (5), 77 (11), 68 (7), 65 (23), 63 (13), 62 (5), 51 (8), 50 (5). ^1H NMR (500.16 MHz, CDCl_3): δ 7.39–7.42 (m, 2H), 7.22 (d, $J = 8.0$ Hz, 2H), 2.36 (s, 3H). ^{13}C NMR (125.77 MHz, CDCl_3): δ 140.29, 131.00, 130.72, 120.57, 111.07 (SCN), 21.19.




Compound 3j (Table 3, entry 10): MS (EI): m/z (%): 171 (37) [M^+], 170 (9), 169 (100) [M^+], 144 (5), 143 (7), 142 (13), 135 (6), 134 (56), 133 (10), 125 (13), 113 (6), 111 (18), 108 (15), 107 (6), 79 (5), 75 (29), 74 (10), 73 (6), 69 (9), 63 (9), 51 (5), 50 (13). ^1H NMR (500.16 MHz, CDCl_3): δ 7.45–7.48 (m, 2H), 7.40–7.42 (m, 2H). ^{13}C NMR (125.77 MHz, CDCl_3): δ 136.25, 131.52, 130.52, 122.84, 110.02 (SCN).




Compound 3k (Table 3, entry 11): MS (EI): m/z (%): 187 (5), 186 (13), 185 (100) [M^+], 159 (7), 158 (9), 153 (21), 141 (25), 140 (7), 127 (20), 126 (12), 115 (19), 114 (7), 79 (10), 77 (7), 75 (5), 63 (5). ^1H NMR (500.16 MHz, CDCl_3): δ 7.95 (d, $J = 2.0$ Hz, 1H), 7.84 (d, $J = 8.5$ Hz, 1H), 7.80–7.82 (m, 1H), 7.75–7.78 (m, 1H), 7.51–7.55 (m, 2H), 7.95 (dd, $J = 8.5$ Hz, 2.0 Hz, 1H). ^{13}C NMR (125.77 MHz, CDCl_3): δ 133.65, 133.10, 130.32, 129.87, 128.00, 127.71, 127.66, 127.62, 126.25, 121.31, 110.68 (SCN).




Compound 3l (Table 3, entry 12): MS (EI): m/z (%): 137 (5), 136 (56) [M^+], 79 (6), 78 (100) [$(M - \text{SCN})^+$], 52 (8), 51 (30). ^1H NMR (500.16 MHz, CDCl_3): δ 8.53 (d, $J = 5.0$ Hz, 1H), 7.78 (ddd, $J = 8.0$ Hz, 7.3 Hz, 2.0 Hz, 1H), 7.61 (d, $J = 8.0$ Hz, 1H), 7.29 (dd, $J = 7.3$ Hz, 5.0 Hz, 1H). ^{13}C NMR (125.77 MHz, CDCl_3): δ 150.62, 150.03, 138.55, 122.86, 122.11, 109.06 (SCN).




Compound 4b (Table 4, entry 1): MS (EI): m/z (%): 186 (0.29) [M^+], 129 (6), 118 (7), 117 (100) [$(M - \text{CF}_3)^+$], 115 (18), 85 (5), 84 (7), 83 (35), 69 (44), 60 (5), 59 (5), 57 (12), 56 (96), 55 (62).




Compound 4c (Table 4, entry 2): MS (EI): m/z (%): 214 (0.08) [M^+], 157 (5), 147 (5), 146 (10), 145 (100) [$(M - CF_3)^+$], 115 (12), 84 (10), 83 (12), 71 (10), 70 (19), 69 (63), 68 (5), 57 (24), 56 (30), 55 (43). 1H NMR (500.16 MHz, $CDCl_3$): δ 2.87 (t, $J = 7.5$ Hz, 2H), 1.69 (quin, $J = 7.5$ Hz, 2H), 1.37–1.42 (m, 2H), 1.26–1.34 (m, 8H), 0.89 (t, $J = 7.5$ Hz, 3H). ^{13}C NMR (125.77 MHz, $CDCl_3$): δ 131.39 (q, $J = 305.9$ Hz, SCF_3), 31.90, 30.04, 29.56, 29.23, 29.09, 28.68, 22.77, 14.21. ^{19}F NMR (470.62 MHz, $CDCl_3$): δ -42.20 (s, 3F).




Compound 4d (Table 4, entry 3): MS (EI): m/z (%): 192 (17) [M^+], 92 (8), 91 (100) [$(M - SCF_3)^+$], 65 (13), 63 (5). 1H NMR (500.16 MHz, $CDCl_3$): δ 7.36–7.27 (m, 5H), 4.11 (s, 2H). ^{13}C NMR (125.77 MHz, $CDCl_3$): δ 135.16, 130.78 (q, $J = 307.0$ Hz, SCF_3), 129.07, 129.01, 128.16, 34.42. ^{19}F NMR (470.62 MHz, $CDCl_3$): δ -42.64 (s, 3F).



Compound 4h (Table 4, entries 4 and 5): MS (EI): m/z (%): 194 (5), 193 (9), 192 (97) [M^+], 173 (5), 125 (5), 124 (7), 123 (100) [$(M - CF_3)^+$], 122 (7), 121 (12), 91 (37), 79 (26), 78 (8), 77 (19), 69 (14), 65 (8), 63 (8), 51 (7). 1H NMR (500.16 MHz, $CDCl_3$): δ 7.53 (d, $J = 8.0$ Hz, 2H), 7.22 (d, $J = 8.0$ Hz, 2H), 2.38 (s, 3H). ^{13}C NMR (125.77 MHz, $CDCl_3$): δ 141.53, 136.54, 130.40, 129.89 (q, $J = 308.3$ Hz, SCF_3), 121.05, 21.47. ^{19}F NMR (470.62 MHz, $CDCl_3$): δ -44.17 (s, 3F).




Compound 4i (Table 4, entries 6 and 7): MS (EI): m/z (%): 209 (6), 208 (63) [M^+], 141 (5), 140 (7), 139 (100) [$(M - CF_3)^+$], 124 (11), 96 (15), 95 (18), 77 (5), 70 (8), 69 (12), 63 (6). 1H NMR (500.16 MHz, $CDCl_3$): δ 7.55–7.58 (m, 2H), 6.91–6.94 (m, 2H), 3.83 (s, 3H). ^{13}C NMR (125.77 MHz, $CDCl_3$): δ 162.01, 138.43, 129.78 (q, $J = 307.1$ Hz, SCF_3), 115.16, 115.00, 55.56. ^{19}F NMR (470.62 MHz, $CDCl_3$): δ -44.92 (s, 3F).




Compound 4j (Table 4, entries 8 and 9): MS (EI): m/z (%): 214 (32) [M^+], 213 (8), 212 (87) [M^+], 193 (6), 145 (36) [$(M - CF_3)^+$], 144 (8), 143 (100) [$(M - CF_3)^+$], 108 (55), 99 (9), 82 (6),

75 (9), 74 (6), 73 (6), 69 (17), 63 (11), 50 (7). ^1H NMR (500.16 MHz, CDCl_3): δ 7.57–7.59 (m, 2H), 7.38–7.41 (m, 2H). ^{13}C NMR (125.77 MHz, CDCl_3): δ 137.86, 137.72, 129.96, 129.47 (q, $J = 308.4$ Hz, SCF_3), 122.95. ^{19}F NMR (470.62 MHz, CDCl_3): δ -43.78 (s, 3F).



Compound 4k (Table 4, entry 10): MS (EI): m/z (%): 230 (5), 229 (14), 228 (100) [M^+], 160 (7), 159 (54) [$(M - \text{CF}_3)^+$], 158 (5), 116 (6), 115 (57), 114 (5). ^1H NMR (500.16 MHz, CDCl_3): δ 8.18 (s, 1H), 7.82–7.87 (m, 3H), 7.64–7.66 (m, 1H), 7.52–7.58 (m, 2H). ^{13}C NMR (125.77 MHz, CDCl_3): δ 137.17, 134.03, 133.53, 131.94, 129.89 (q, $J = 308.3$ Hz, SCF_3), 129.36, 128.32, 128.07, 127.92, 127.15, 121.66. ^{19}F NMR (470.62 MHz, CDCl_3): δ -43.47 (s, 3F).



Compound 4m (Table 4, entry 11): MS (EI): m/z (%): 363 (0.12) [$(M - \text{SCF}_3)^+$], 331 (2.4) [$(M - \text{SCF}_3)^+$], 211 (9), 210 (13), 197 (12), 170 (9), 169 (100), 139 (16), 127 (23), 115 (18), 110 (5), 109 (65), 103 (14), 102 (7), 99 (5), 98 (6), 97 (20), 85 (7), 81 (9), 70 (5), 69 (11).

NMR Spectra

